
DexCom (DXCM) is anticipated to report quarterly EPS of $0.45, a 4.7% year-over-year increase, on revenues of $1.12 billion, up 11.8%, with consensus estimates remaining stable over the past 30 days. A notable detail in analyst projections is a significant 32% year-over-year decline in hardware revenue, which is expected to be more than offset by robust 14.5% growth in sensor and other revenues, indicating a shift in the company's revenue mix. Despite recent underperformance against the S&P 500, DXCM maintains a Zacks Rank #2 (Buy).
DexCom (DXCM) is positioned for its upcoming earnings announcement with consensus estimates projecting solid growth, including a 4.7% year-over-year increase in EPS to $0.45 and an 11.8% rise in revenue to $1.12 billion. The stability of the consensus EPS estimate over the last 30 days suggests a firm conviction among analysts. A critical detail within the forecasts is a significant revenue mix shift: 'Hardware' revenue is expected to contract by a substantial 32% to $38.99 million, while the 'Sensor and other' segment is projected to drive growth with a 14.5% increase to $1.08 billion. This highlights a strategic transition towards a recurring-revenue model based on consumables. Geographically, growth is expected to be robust in both the U.S. (+10.6% to $809.70 million) and International markets (+14.3% to $311.29 million), indicating successful global expansion. Despite these positive indicators and a Zacks Rank #2 (Buy) suggesting potential outperformance, the stock's +3.1% return over the past month has lagged the S&P 500 composite's +4.9% gain, setting the stage for a pivotal earnings report.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment